Current Report · Items 1.01, 8.01, 9.01 · 8-K
CTT PHARMACEUTICAL HOLDINGS, INC.
CTTHOTCEQUITYCurrent
Entry into a Material Definitive Agreement · Other Events
Item 1.01 Entry into a Material Definitive Agreement.
Company context
CTT Pharmaceutical Holdings, Inc. is a pharmaceutical technology company specializing in oral drug delivery systems designed to provide rapid onset, enhanced patient convenience, and efficient absorption. The Company’s patented micelle based thin film platform is intended to offer a novel alternative to traditional dosage forms across pharmaceutical, therapeutic, and nutraceutical markets. CTT is focused on integrating scientific validation, scalable manufacturing, and regulatory preparedness to support long-term growth and product innovation.
Current securities
Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) has added Karen Larson as an Independent Board Member. Mrs. Larson is a Certified Financial Planner(CFP) and has experience in running companies. Karen created an analytical reporting business that was sold to Morningstar and also served as a Senior Vice President, Investment Banker at Chase Manhattan Bank and since 2017 has spent the past 9 years as a founder of Broad Avenue Studios, Inc., a commercial and residential real company.